Version May 2024
| Study | Regimen | Patient population | Total number of patients | Number of patients with breast cancer and brain metastases | Objective response rate (percent) | TTP/PFS | Comments |
| Rosner et al[1] | Various (CFP, CFPMV, MVP, CA) | Breast cancer | 100 | 100 | 50 | NR | Case series |
| Boogerd et al[2] | Oral CMF (n=20), or CAF (n=2) | Breast cancer | 22 | 22 | 54 | NR | Case series |
| Friedman et al[3] | Temozolomide 150 mg/m2 days 1-7, 15-21, every 28 days | Solid tumors | 52 | 15 | 6 | NR | No responses seen in breast cancer patients |
| Siena et al[4] | Temozolomide 150 mg/m2 days 1-7, 15-21, every 28 days | Solid tumors | 62 | 21 | 19 (in subset of patients with breast cancer) | 1.9 months | |
| Trudeau et al[5] | Temozolomide 150 mg/m2 days 1-7, 15-21, every 28 days | Breast cancer | 19 | 5 | 0 | NR | |
| Rivera et al[6] | Escalating doses of capecitabine and temozolomide | Breast cancer | 24 | 24 | 18 | 3 months | |
| Franciosi et al[7] | Cisplatin 100 mg/m2 day 1 Etoposide 100 mg/m2 days 1, 3, and 5, every 21 days | Solid tumors | 107 | 56 | 38 (in subset of patients with breast cancer) | 4 months | No prior radiation therapy allowed; 36 percent of patients had not had prior systemic treatment for breast cancer |
| Christodoulou et al[8] | Temozolomide 150 mg/m2 days 1-5 Cisplatin 75 mg/m2 day 1, every 21 days | Solid tumors | 32 | 15 | 40 (in subset of patients with breast cancer) | 2.9 months | |
| Lin et al[9] | Lapatinib | HER2+ breast cancer | 39 | 39 | 2.6 | 3 months | 64 percent had two or more prior lines of systemic treatment (trastuzumab plus chemotherapy) |
| Lin et al[10] | Lapatinib | HER2+ breast cancer | 237 | 237 | 6 | 2.4 months | All patiens previously treated with radiation therapy; overall survival was 6 months |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
